Immunotherapy for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors. Here, we review the molecular c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of surgical oncology 2021-03, Vol.123 (3), p.751-759
Hauptverfasser:	Carpenter, Eileen, Nelson, Sarah, Bednar, Filip, Cho, Clifford, Nathan, Hari, Sahai, Vaibhav, Magliano, Marina Pasca, Frankel, Timothy L.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Cancer Vaccines - therapeutic use Carcinoma, Pancreatic Ductal - immunology Carcinoma, Pancreatic Ductal - therapy Clinical Trials, Phase I as Topic Clinical Trials, Phase II as Topic Humans Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Immunotherapy - methods microenvironment Pancreatic cancer Pancreatic Neoplasms - immunology Pancreatic Neoplasms - therapy Randomized Controlled Trials as Topic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors. Here, we review the molecular components responsible for the immune‐privileged state in PDAC and provide an overview of the immunotherapeutic strategies for PDAC including vaccine therapy, checkpoint blockade, myeloid‐targeted therapy, and immune agonist therapy.
ISSN:	0022-4790 1096-9098
DOI:	10.1002/jso.26312